David A. Bristol

Director/Board Member at HCF Enterprises, Inc.

Consumer Services

Health Technology

Profile

David A.
Bristol is currently a Director at HCF Enterprises, Inc. and Sentinel Private Equity XVI Fund.
He was previously a Director at Nanospectra Biosciences, Inc. and a Geophysicist at Exxon Co. USA from 1988 to 1991.
Bristol received his undergraduate degree from Brown University and his graduate degree from The University of Texas at Austin.

David A. Bristol active positions

Companies	Position	Start
HCF Enterprises, Inc.	Director/Board Member	-
Sentinel Private Equity XVI Fund	Director/Board Member	-

All active positions of David A. Bristol

Former positions of David A. Bristol

Companies	Position	End
Exxon Co. USA	Corporate Officer/Principal	1991-01-01
Nanospectra Biosciences, Inc. Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX.	Director/Board Member	-

See the detail of David A. Bristol's experience

Training of David A. Bristol

Brown University	Undergraduate Degree
The University of Texas at Austin	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David A. Bristol's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
Nanospectra Biosciences, Inc. Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX.	Health Technology
Exxon Co. USA
Sentinel Private Equity XVI Fund
HCF Enterprises, Inc.

See company connections

Stock Market
Insiders
David A. Bristol